Inhibition of DNA methylation has become an established therapeutic approach in MDS, although the mechanism of action remains only partially elucidated at the molecular level, primarily involving a defective DNA methylation pattern and the presence of variants in genes involved in this process (e.g., DNMT3A, TET2, IDH1/2). This evidence concerns the gene TET2 and myelodysplastic syndrome.